Systemic immunological effects of cytokine genes injected into skeletal muscle. by Raz, E. et al.
Proc. Natl. Acad. Sci. USA
Vol. 90, pp. 4523-4527, May 1993
Immunology
Systemic immunological effects of cytokine genes injected into
skeletal muscle
(immune modulation/gene delivery)
EYAL RAZ*, AKIRA WATANABE*, STEPHEN M. BAIRDt, ROBERT A. EISENBERGt, TYLER B. PARR*,
MARTIN LOTZ*, THOMAS J. KIPPs*, AND DENNIS A. CARSON*
*Department of Medicine and The Sam and Rose Stein Institute for Research on Aging, University of California, San Diego, La Jolla, CA 92093-0663;
tDepartment of Pathology, Veterans Administration Medical Center, San Diego, CA 92161; and tDepartment of Medicine, Division of Rheumatology
and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7280
Communicated by J. Edwin Seegmiller, February 22, 1993
ABSTRACT Somatic gene therapy is an interesting ap-
proach for the delivery of cytokines for prolonged periods. The
present experiments show that direct inijections into mouse
skeletal muscle of cDNA expression vectors encoding interleu-
kin 2 (IL-2), IL-4, or type P1 transforming growth factor
(TGF-j31) induce biological effects characteristic of these cy-
tokines in vivo. Mice injected intramuscularly with a vector
encoding IL-2 had enhanced humoral and cellular immune
responses to an exogenous antigen, transferrin, that was de-
livered at a separate site. These IL-2 effects were abolished by
coadministration of a vector directing synthesis of TGF-f31.
The TGF-.31 vector by itself depressed the anti-transferrin
antibody response and caused an 8-fold increase in plasma
TGF-f81 activity. The TGF-p1 plasmid injection did not cause
muscle infiltration with monocytes or neutrophils and there
was no evidence for fibrotic changes. Muscle injection with a
cDNA encoding IL-4 selectively increased IgGl levels but did
not alter the cellular immune response to transferrin. In
lupus-prone mice (MRL/lpr/lpr), injection with IL-2 expres-
sion vectors increased and TGF-fi1 vectors decreased auto-
antibodies to chromatin. These results demonstrate that intra-
muscular injection of cytokine genes, in the absence of infec-
tious viral vectors, can regulate humoral and cellular immune
responses in vivo.
Cytokines and related peptide growth factors are being used
therapeutically with increasing success. However, their ap-
plications have been limited, because of the necessity to
administer relatively large amounts of recombinant proteins
that usually have a short half-life. Somatic gene therapy is a
potential approach to overcome this problem. Recent exper-
iments have demonstrated the functionality of genes inserted
into myoblasts. Three expression strategies have been used:
(i) transplantation of transfected myoblasts (1, 2), (ii) viral
vectors (3), and (iii) direct intramuscular (i.m.) plasmid
cDNA injection (4, 5).
The advantages of direct DNA injection into skeletal
muscles of living animals are the simplicity and safety of the
technique. It can be accomplished without the use of infec-
tious virus and without the need for integration of the gene of
interest into the host genome. In addition, the level and
persistence of expression obtained in some studies suggests
that functional genes may be administered repetitively in a
"drug-like" manner. However, this strategy has not yet been
shown to produce biologically active growth factors in vivo,
and there is no information to support whether or not local
DNA injection can result in systemic effects with potential
therapeutic significance.
This study was designed to test the possibility that skeletal
muscle can be used to express biologically active cytokines
after injection with the analogous plasmid cDNA(s). The
results demonstrate that injections of genes encoding inter-
leukin 2 (IL-2), IL-4, and type (31 transforming growth factor
(TGF-,81) induce systemic immunological effects that are
specific functions of the respective cytokine proteins.
MATERIALS AND METHODS
Construction of Expression Vectors for IL-2, TGF-,Bl, and
IL-4. The cDNAs for human IL-2 (ATCC 67618), TGF-f1
(ATCC 59954), and mouse IL-4 (ATCC 37561) were sub-
cloned into the vector pBSII SK to generate 5' HindIII and
3' Sma I sites. These were used to replace the HindIH/
BamHI luciferase cDNA fragment in the expression vector
pRSVL (4). The resulting expression vectors (pRSVIL2,
pRSVTGF(31, and pRSVIL4) contain the Rous sarcoma virus
long terminal repeat promoter, and simian virus 40 polyade-
nylylation site. Plasmid DNA was purified from transformed
DH5a Escherichia coli with Qiagen kits (Chatsworth, CA).
The activities of the three vectors were confirmed by
transient lipofection ofmouse C2C12 myoblasts (ATCC CRL
1772) as described (6). In each case, supernatants obtained 48
hr after lipofection contained biologically active cytokine, as
determined by the lymphocyte-activation factor assay, using
murine C3H/HeF thymocytes, in the presence or absence of
the appropriate specific neutralizing antibodies (R&D Sys-
tems, Minneapolis).
Experimental Design. Five-week-old BALB/c mice were
purchased from The Jackson Laboratory. At 6 weeks of age
(day 0) animals were divided into four groups offour mice. At
days 0, 7, and 14, groups 2-4 were injected i.m. with a
28-gauge needle at five different sites in the right thigh with
a total of 100 ,ug of plasmid DNA (pRSVIL2, pRSVTGFP1,
or pRSVIL4) dissolved in 100 ,ul of normal saline. Group 1
was injected with 100 ,ul of normal saline. At days 3, 10, and
17 (3 days after the cytokine gene injections), all animals were
immunized with 100 ,ug ofkeyhole limpet hemocyanin (KLH)
(Sigma), dispersed in 100 ,l of Imject Alum (aluminum
hydroxide; Pierce) i.m. in the same thigh. The second set of
experiments followed a similar protocol. Five groups of eight
mice each were injected in the right thigh with 100 .g of
plasmidDNA (pRSVIL2, pRSVTGFf31, orpRSVIL4; groups
2-4, respectively). Group 1 was injected with normal saline,
while group 5 was injected with 100 jig of pRSVIL2 and 100
jig of pRSVTGF,81. In contrast to the first experiments, the
antigen human transferrin (Sigma) was injected under the
same conditions i.m. in the left shoulder. At day 56 or 63,
Abbreviations: IL, interleukin; TGF-,B, type (3 transforming growth
factor; KLH, keyhole limpet hemocyanin; DTH, delayed-type hy-
persensitivity.
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mice were injected s.c. with 50 ug of antigen (KLH or
transferrin, respectively) suspended in 50 ,ul of normal saline.
All animals were bled weekly from the retroorbital plexus for
measurement of antibody levels. Six-week-old MRL/lpr/lpr
mice (The Jackson Laboratory) were injected three times at
4-week intervals, following the same method with 100 ,ug of
pRSVIL2, pRSVTGF/31, or pRSVnull (10 mice per group).
Mice were bled at 16 weeks, 2 weeks after the last injection,
for measurement of anti-chromatin antibody levels. In the
transferrin experiment, three mice from the pRSVTGF,B1
group, one mouse from the control group, and one mouse
from the pRSVIL2 group, died during bleeding or anesthesia.
Antibody Assays. Wells of microtiter plates (Costar 3590)
were coated with human transferrin [100 ul per well; 10
,ug/ml in borate-buffered saline, pH 8.0 (BBS), overnight]
washed with the same buffer, and quenched with a 1% bovine
serum albumin (BSA) solution in BBS. After washing twice
in BBS/0.5% Tween 20, serum samples diluted 1:1000 in
phosphate-buffered saline, pH 7.4 (PBS), were added to
duplicate wells. After overnight incubation at 4°C, the plates
were washed with BBS/Tween and incubated with biotiny-
lated anti-mouse IgG and IgM (Jackson Laboratories, West
Grove, PA) diluted 1:8000 in PBS. After 1 hr of incubation
with peroxidase-labeled streptavidin (Kirkegaard and Perry
Laboratories, Gaithersburg, MD) diluted to 1:2000 in PBS
containing 1% BSA, the plates were washed four times with
BBS/Tween and incubated with TMB peroxidase substrate
(Kirkegaard and Perry Laboratories). Thirty minutes later,
absorption at 450 nm was measured in a Titertek multiscan
meter (Flow Laboratories). Each assay mixture included a
standard mouse anti-KLH or anti-transferrin antiserum that
was diluted serially starting at 1:5000. In the transferrin
experiment, the absorption values were converted to relative
antibody concentrations. In the description of the results, 1
is defined as the antibody level in a 1:5000 dilution of the
standard antiserum.
Total IgG and IgGl concentrations were determined in the
transferrin experiment with radial immunodiffusion kits (The
Binding Site, San Diego) according to the manufacturer's
instructions.
Antibodies to chromatin were assayed by ELISA as de-
scribed (7). The ELISA absorbance values are referred to a
standard curve that was established with a strongly positive
reference serum. The results are the dilution of the standard
curve, which gave the same absorbance as the test sera x 106,
and have been shown to represent a linear measure of the
amount of antibody present. The absolute units are arbitrary
and are expressed as equivalent dilution factors.
Measurement of Circulating Levels of TGF-g31 Protein. To
determine whether gene administration leads to a sustained
increase in circulating cytokine levels, mice were bled at
week 6, 4 weeks after the last gene injection, and the plasma
samples were assayed for TGF-,B1 activity by the CCL64
mink lung cell proliferation assay, slightly modified as de-
scribed (8). Rabbit antibody that specifically neutralizes
TGF-,B1, but not TGF-,B2 or TGF-/33, was purchased from
R&D Systems (Minneapolis).
Measurement of Delayed-Type Hypersensitivity (DTH) Re-
sponses. To determine whether injection of cytokine genes
modulates cellular immunity, DTH responses were tested by
footpad swelling 48 hr after antigen challenge. At day 70, 100
,ug of transferrin in 100 Al of normal saline was injected into
the right hind footpad. Footpad thickness was measured with
calipers before and 48 hr after injection, and the difference
between these measurements was calculated.
Histological Evaluation. At day 91, three mice from each
group of the transferrin experiment were sacrificed. Muscles
into which the genes had been injected were fLxed in 10%
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FIG. 1. Effects of cytokine gene injections on antibody re-
sponses. Groups of four BALB/c mice were injected i.m. on days 0,
7, and 14 with expression vectors for IL-2 and IL-4 (A) or TGF-,B(B).
On days 3, 10, and 17, animals were immunized at the same site with
KLH. Following the same time schedule of injection, groups of
eight mice were injected with expression vectors for IL-2 (C),
TGF-,81 (D), or IL-2 plus TGF-,81 (E). However, here the animals
were immunized at a separate site with human transferrin. Antibody
responses were measured by ELISA at the times indicated on the
abscissa. Anti-transferrin antibody results are expressed as mean
relative antibody concentrations ± SEM compared to a standard
antiserum.
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Table 1. Effects of i.m. cytokine gene injections on total IgG levels following immunization
with transferrin
Week 0 Week 5 Week 10 Week 11
Control 1716 ± 72 4863 ± 234 7,475 ± 627*t 10,182 ± 578*
TGF-,B 1956 ± 165 4404 ± 419t 7,456 ± 232*t 9,732 ± 528*
IL-2 1907 ± 55 5085 ± 168 10,977 ± 790 12,146 ± 348
IL-4 1828 ± 41 5572 ± 434 10,372 ± 982 11,651 ± 553
TGF-f/IL-2 1892 + 101 5197 ± 124 8,330 ± 545*t 9,817 ± 872*t
Total IgG levels were determined by radial immunodiffusion. Values are shown as mg/liter and
represent means ± SEM.
*P < 0.05 vs. IL-2.
tp < 0.05 vs. IL-4.
Statistical Analysis. Data from each experiment were com-
pared by one factorial ANOVA.
RESULTS
Effects of Cytokine Gene Injection on Antibody Responses to
Foreign Antigens. In the first set of experiments, we deter-
mined the effects of i.m. cytokine gene injections on antibody
responses to a foreign antigen KLH that was injected at the
same site as the plasmid. Antibodies to KLH reached higher
levels in the pRSVIL2 and pRSVIL4 groups than in the
control group (Fig. 1A). In contrast, anti-KLH antibodies
were lower in the pRSVTGFp1 group than in the control
group (Fig. 1B). To determine whether the cytokine genes
exerted their effects systemically, and not only at the regional
lymph node, a second set of experiments was performed in
which antigen (transferrin) and cytokine vectors were in-
jected at two different sites. Antibodies to transferrin were
highest in the pRSVIL2 group (Fig. 1C) and lowest in the
pRSVTGFJ31 group (Fig. 1D). These results showed that
injection of the two plasmids was capable of stimulating or
inhibiting the antibody response. In several in vitro systems,
TGF-,8 can antagonize the effects of IL-2. It is unknown
whether TGF-,B can have similar activities in vivo. Experi-
ments were thus performed in which plasmids encoding IL-2
or TGF-p1 were injected simultaneously. Anti-transferrin
antibody levels in the group that received both pRSVIL2 and
pRSVTGFf81 were indistinguishable from the pRSVTGF.81
group (Fig. 1E), demonstrating that TGF-,B1 expression
completely neutralized the IL-2 effect. Mean anti-transferrin
antibody levels in the pRSVIL4 group were higher but not
significantly different from the control group (2.3 ± 0.4 vs.
1.7 ± 0.36 mg/liter in the 11th week). In control experiments,
injections of the pRSV plasmid without any cytokine insert
had no consistent effect on antibody levels (results not
shown). Thus, the immunologic consequences of the cyto-
kine gene injections cannot be attributed to nonspecific
effects ofDNA on interferon levels or to trace contamination
with endotoxin.
Levels of Total IgG and IgGl. Levels of total IgG were
measured in the sera from the transferrin-injected mice. The
highest IgG levels were observed in the pRSVIL2 and the
pRSVIL4 groups after 10 and 11 weeks; the lowest levels
were detected in the pRSVTGF,81 group (Table 1). TGF-p1
plasmid injections completely inhibited the IL-2-mediated
increase. The levels of total IgG in the pRSVIL2/
pRSVTGF,81 group were similar to those in the pRSVTGF81
group. The mice injected with pRSVIL4 had significantly
higher concentrations of IgGl than the other groups (Table
2).
DTH. To determine whether cytokine gene injections can
modulate cellular immunity, DTH responses were tested by
a footpad swelling assay after antigen challenge. As shown in
Fig. 2, there was a highly significant increase in footpad
swelling in pRSVIL2-injected mice, as compared to the
control group. Coinjection of pRSVTGFI81 completely in-
hibited the IL-2 effect.
Levels of Circulating TGF-813. The mean plasma levels of
TGF-,B1 at week 6, 4 weeks after the last pRSVTGF,31
injection, were 2.6 ng/ml as compared to only 0.32 ng/ml in
the pRSVIL2-injected or untreated animals, which repre-
sents an 8-fold difference. TGF-f3 activity was neutralized by
specific antibodies to TGF-,81 (Table 3).
Histological Evaluation. Sections from muscles that had
been injected with plasmidDNA showed multiple discrete loci
of lymphocyte and macrophage infiltration in the pRSVIL2
and the pRSVIL4 groups (results not shown). In contrast,
there was no muscle infiltration with monocytes or neutrophils
in the pRSVTGF,8 group, nor were there any detectable signs
of fibrosis.
Anti-Chromatin Antibodies. The results from the transfer-
rin studies showed that plasmid DNA injections induced
biological effects characteristic of the three cytokines during
cellular or humoral immune responses to a foreign antigen.
To determine whether this approach is also effective in
modulating ongoing pathological immune responses, we
tested the IL-2 and TGF-f81 plasmids in MRL/lpr/lpr mice,
which produce high titers of autoantibodies and are used as
a model of systemic lupus erythematosus. Titers of autoanti-
bodies to chromatin in the MRL/lpr/lpr mice were signifi-
cantly increased in the pRSVIL2 group. The lowest titers
were observed in the pRSVTGF(81 group. The mean differ-
ence between the two groups was almost 7-fold (Fig. 3).
DISCUSSION
Gene expression in muscle tissue following injection of
plasmid cDNA has been demonstrated previously in exper-
iments using reporter gene constructs (1, 2, 4). However, the
results presented here demonstrate that direct injection of
Table 2. Injection of IL-4 gene increases IgGl levels following immunization with transferrin
Week 5 Week 10 Week 11
Control 1320 ± 75 (0.27)* 2401 ± 121 (0.32)* 3562 ± 167 (0.35)*
TGF-,8 1466 ± 76 (0.33)* 2568 ± 252 (0.34)* 3642 ± 171 (0.37)*
IL-2 1570 ± 95 (0.31)* 2797 ± 153 (0.26)* 3984 ± 163 (0.33)*
IL-4 2352 ± 207 (0.42) 4033 ± 302 (0.39) 4865 ± 343 (0.42)
IgGl levels were determined by radial immunodiffusion. Values are shown as mg/liter and represent
means ± SEM. Numbers in parentheses denote IgGl/IgG ratio at the same time point.
*P < 0.05 vs. IL-4.
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FIG. 2. Effects of cytokine gene injections on DTH responses.
Animals in each group were challenged with 100 Mg of transferrin
injected in the right hind footpad. Footpad thicknesses were mea-
sured before and 48 hr after injection, and differences between
preinjected and postinjected measurements were calculated. Results
are expressed as means ± SEM.
cDNA expression vectors into muscle can produce biologi-
cally significant systemic effects. Cytokine genes and anti-
gens were injected into experimental animals at different
times and at disparate sites. Moreover, the immunologic
actions of the cytokine genes persisted for weeks after
administration. These results indicate that the effects of the
cytokine genes were exerted systemically.
Injection of the IL-2 gene augmented the antibody re-
sponse to immunization with KLH or transferrin, elevated
total plasma IgG levels, and increased the magnitude of the
DTH response in antigen-challenged animals. These results
demonstrate that IL-2 gene injection can reproduce the
central role of IL-2 in T-cell-dependent immune responses
(9). Injection of the IL-4 gene increased total IgG levels and
selectively upregulated IgGl concentrations (10) but did not
intensify the DTH response to antigen challenge (11). These
effects are consistent with the established role of IL-4 in
stimulation of immune responses mediated by the TH2 lym-
phocyte subset (12).
TGF-,B1 is a multifunctional cytokine that generally antag-
onizes the actions of IL-2 (13). Injection of the TGF-31 gene
inhibited the humoral and cellular immunostimulatory effects
of the IL-2 gene (14). Similarly, mice injected with the
TGF-,B1 gene alone had reduced antibody responses to trans-
ferrin, as compared to controls, presumably due to its im-
munosuppressive effects on B and T cells (15-18).
These data demonstrate that cytokine gene injections can
successfully modulate immune responses to foreign antigens.
This can be achieved in a stimulatory or inhibitory fashion,
as shown for IL-2 and IL-4 vs. TGF-,B1, respectively. More-
over, simultaneous administration ofTGF-,B1 can completely
inhibit the immunostimulatory effects of IL-2 and IL-4. The
same pattern of results was observed in the MRL/lpr/lpr
mice. Injection of the IL-2 gene increased dramatically the
level of anti-chromatin antibodies, while injection of the
TGF-,B1 gene reduced the level of this autoantibody.
Table 3. Circulating TGF-, activity
Total TGF,8 TGF-,B1
Plasmid activity activity
pRSVTGFj3l 2.6 ± 1.08 2.6
pRSVIL2 0.32 ± 0.11 0.32
Plasma samples from mice injected with either pRSVTGF.81 or
pRSVIL2 were collected 4 weeks after the last plasmid injection.
Samples were diluted 1:10, acidified to pH 4, neutralized, and tested
in triplicate in the CCL64 assay for TGF-,B activity. Aliquots of the
samples were also incubated with neutralizing rabbit antibody spe-
cific for TGF-,B1 (10 ng/ml) before their addition to the CCL64 assay
mixture. Preimmune rabbit IgG did not change the levels of TGF-,B
activity. TGF-p levels were derived by comparison with a standard
curve containing recombinant TGF-,1l (R&D Systems), are shown in
ng/ml, and represent means ± SE from three samples per group.
FiG. 3. Effect of cytokine gene injections on autoantibodies to
chromatin. Groups of 10 MRL/lpr/lpr mice were injected i.m. every
4 weeks with pRSVIL2, pRSVTGF(3, or pRSVnull (PL. null; without
any insert). Anti-chromatin antibodies were measured by ELISA at
16 weeks of age. Results are expressed as equivalent dilution factors.
Cytokines are often difficult to detect in serum, due to their
labilities, to their short half-lives, and to the relative insen-
sitivity and imprecision of the available detection systems
(19-21). Despite these difficulties, we detected an 8-fold
increase in TGF-131 concentrations in BALB/c mice 4 weeks
after the last administration of the TGF-,B1 gene.
TGF-p is secreted by most cell types in a latent precursor
form, which can be activated enzymatically or by exposure
to an acidic or basic milieu. The TGF-(31 construct used in the
present studies encoded the precursor protein, and, consis-
tent with this, we detected only latent TGF-f3 in cells trans-
fected with this vector in vitro or in the plasma of mice
receiving i.m. injections. However, TGF-,B inhibited cellular
and humoral immune responses when injected into muscles
distinct from the site of antigen injection. This suggests that
TGF-,B is activated in lymphoid tissues. There was no de-
tectable evidence for local manifestations of TGF-,( effects at
the sites of plasmid injection. Specifically, we did not find
muscle infiltration with monocytes or neutrophils or signs of
fibrotic changes. The present results thus suggest that TGF-f3
can be administered by gene injection without inducing
fibrosis and inflammatory cell infiltration, effects that would
argue against the therapeutic use of TGF-p as an immuno-
suppressive agent.
Many different cytokines have been described in the past
several years. The large number of different cytokines has
made it difficult to ascertain their respective physiologic roles
and to determine how they interact to regulate immune and
inflammatory responses. Intramuscular injection of expres-
sion vectors directing the synthesis ofeach ofthese cytokines
may provide a simple and powerful method to address this
problem. It obviates the need to express, purify, and admin-
ister multiple different recombinant cytokine proteins. More-
over, this approach should facilitate the in vivo analysis of
cytokine genes that have been changed in the laboratory to
produce proteins with altered pharmacologic properties.
Several potential clinical applications of cytokine gene
therapy can be proposed. The production of TGF-31 or
IL-10, which is a potent immunosuppressant of monocyte
function (13), by transfected skeletal muscles may help to
control severe autoimmune and inflammatory diseases. The
coadministration of particular combinations of cytokine
genes may be able to modulate the immune response to
vaccination by favoring the formation of cytotoxic T cells
versus neutralizing antibodies. Secretion of IL-2 may be
efficacious in immune deficiency states or in patients with
tumors (22). In conclusion, the present results suggest that
expression of biologically active cytokines, following plas-
mid injection, and the resulting modulation of cellular re-
sponses provide a basis for systemic delivery of biologically
active proteins in a wide spectrum of immunologic diseases.
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